Dagan Ron
Ben Gurion University of the Negev, Soroka University Medical Center, Beer-Sheva 84101, Israel.
Vaccine. 2008 Jun 16;26 Suppl 2:B16-8. doi: 10.1016/j.vaccine.2008.05.019.
Pneumococcal conjugate vaccines (PCVs) have significant efficacy in preventing acute otitis media caused by vaccine-type pneumococcal serotypes. This article questions whether experiences with pneumococcal otitis can be applied to pneumococcal pneumonia, and examines whether PCVs have a class effect, meaning do different PCVs offer equivalent protection against the same outcome of pneumococcal disease. While PCVs appear to have a class effect in general, variability in serotype-specific antibody concentrations makes extrapolation from one vaccine to another difficult. Antibody concentrations or measurements of antibody functionality may provide a means to anticipate a predicted outcome in pneumococcal pneumonia for certain emergent vaccine candidates.
肺炎球菌结合疫苗（PCV）在预防由疫苗型肺炎球菌血清型引起的急性中耳炎方面具有显著疗效。本文质疑肺炎球菌性中耳炎的经验是否可应用于肺炎球菌肺炎，并研究PCV是否具有类效应，即不同的PCV对肺炎球菌疾病的相同结局是否提供同等保护。虽然PCV总体上似乎具有类效应，但血清型特异性抗体浓度的变异性使得从一种疫苗推断到另一种疫苗变得困难。抗体浓度或抗体功能的测量可能为预测某些新出现的候选疫苗在肺炎球菌肺炎中的预期结果提供一种方法。
